Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.
The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.
CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.